Noradrenergic α1 Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial
Open Access
- 3 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2) , e30854
Abstract
Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the noradrenergic α1 receptor antagonist doxazosin on the positive subjective effects of cocaine. Thirteen non-treatment seeking, cocaine-dependent volunteers completed this single-site, randomized, placebo-controlled, within-subjects study. In one study phase volunteers received placebo and in the other they received doxazosin, with the order counterbalanced across participants. Study medication was masked by over-encapsulating doxazosin tablets and matched placebo lactose served as the control. Study medication treatment was initiated at 1 mg doxazosin or equivalent number of placebo capsules PO/day and increased every three days by 1 mg. After receiving 4 mg doxazosin or equivalent number of placebo capsules participants received masked doses of 20 and 40 mg cocaine IV in that order with placebo saline randomly interspersed to maintain the blind. Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood pressure. During treatment with placebo, cocaine produced dose-dependent increases in subjective effect ratings of “high”, “stimulated”, “like cocaine”, “desire cocaine”, “any drug effect”, and “likely to use cocaine if had access” (p<.001). Doxazosin treatment significantly attenuated the effects of 20 mg cocaine on ratings of “stimulated”, “like cocaine”, and “likely to use cocaine if had access” (p<.05). There were trends for doxazosin to reduce ratings of “stimulated”, “desire cocaine”, and “likely to use cocaine if had access” (p<.10). Medications that block noradrenergic α1 receptors, such as doxazosin, may be useful as treatments for cocaine dependence, and should be evaluated further. Clinicaltrials.gov NCT01062945Keywords
This publication has 30 references indexed in Scilit:
- Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine β-HydroxylaseNeuropsychopharmacology, 2010
- Fixed-Dose Combinations as Initial Therapy for HypertensionDrugs, 2009
- Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trialDrug and Alcohol Dependence, 2009
- Controversies in translational research: drug self-administrationPsychopharmacology, 2008
- There and Back Again: A Tale of Norepinephrine and Drug AddictionNeuropsychopharmacology, 2006
- Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effectsPharmacology Biochemistry and Behavior, 2005
- Brain Dopamine and RewardAnnual Review of Psychology, 1989
- Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeysPharmacology Biochemistry and Behavior, 1987
- Clinical Pharmacokinetics of PrazosinClinical Pharmacokinetics, 1980
- Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curveJournal of Pharmacokinetics and Biopharmaceutics, 1978